Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines

Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up

Central and especially peripheral neurotoxicities due to systemic antineoplastic therapy are common and often dose-limiting side effects. In patients with chemotherapy-induced peripheral neurotoxicity (CIPN), recovery is in general partial with residual deficits in most patients. In these Clinical Practice Guidelines, recommendations on diagnosis, prevention and treatment of peripheral neurotoxicity and specific aspects of central neurotoxicity due to antineoplastic therapy will be given. Recommendations regarding immune-related neurotoxicity due to immune checkpoint inhibitors (ICPis) are described in depth in the ESMO Clinical Practice Guidelines on ‘Management of toxicities from immunotherapy’.

Click here to read published version (Annals of Oncology (2020), DOI:https://doi.org/10.1016/j.annonc.2020.07.003)

EANO Conflict of Interest Disclosure

Declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided. Declarations must include any payments, honorarium or arrangement for re-imbursement of expenses, relevant for any aspect of his/her involvement with EANO, that has been provided by commercial companies.

Log in to edit your data

Login